MedTrace Logo

Adductor Canal Block Versus Liposomal Bupivacaine in TKA

NCT04086186 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-09-11

No results posted yet for this study

Summary

This is a randomized prospective study of 60 patients undergoing total knee arthroplasty evaluating the clinical outcomes of liposomal bupivacaine periarticular injections (PAI) when compared to single shot adductor canal block using bupivacaine HCl.

Conditions

  • Total Knee Arthroplasty
  • Post-operative Pain Control

Interventions

PROCEDURE

Liposomal Bupivacaine Peri-articular Injection

A 20mL solution of 266mg of liposomal bupivacaine (Exparel) was mixed with 40mL of normal saline, which was then infiltrated consistently in the posterior capsule, medial and lateral side of the arthrotomy, patella tendon, quadriceps tendon, quadriceps musculature, and subcutaneous soft tissue.

PROCEDURE

Adductor canal block

Anesthesiologist performs preoperative adductor canal block using 15mL of 0.5% Bupivacaine HCl

Sponsors & Collaborators

  • Good Samaritan Regional Medical Center, Oregon

    lead OTHER

Principal Investigators

  • Justin Than, DO · Samaritan Health Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-22
Primary Completion
2018-11-25
Completion
2018-12-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04086186 on ClinicalTrials.gov